Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
135.98(c) 136.52(c) 138.02(c) 138.52(c) 137.52(c) Last
5 756 816 5 380 891 10 745 724 9 543 743 10 485 289 Volume
+0.57% +0.40% +1.10% +0.36% -0.72% Change
More quotes
Financials (USD)
Sales 2019 81 168 M
EBIT 2019 25 628 M
Net income 2019 19 012 M
Debt 2019 1 998 M
Yield 2019 2,74%
Sales 2020 84 602 M
EBIT 2020 27 969 M
Net income 2020 20 821 M
Finance 2020 8 909 M
Yield 2020 2,90%
P/E ratio 2019 19,63
P/E ratio 2020 17,33
EV / Sales2019 4,54x
EV / Sales2020 4,22x
Capitalization 366 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
04/25 | 10:00amShareholder meeting
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
04/19JOHNSON & JOHNSON : TB Alliance and Mylan Announce Global Collaboration to Comme..
AQ
04/19FDA orders companies to stop sale of pelvic surgical mesh in US
AQ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17GENMAB : Announces Net Sales of DARZALEX for First Quarter of 2019
AQ
04/17JOHNSON & JOHNSON : Balversa receives U.S. FDA approval for the treatment of pat..
AQ
04/17JOHNSON & JOHNSON : Higher Drug Sales Aid J&J Results
DJ
04/17JOHNSON & JOHNSON : Wall St edges up on positive earnings data
AQ
04/16JOHNSON & JOHNSON : Qualcomm and Progressive jump while Wave Life Sciences drops
AQ
04/16MARKET SNAPSHOT: Stocks Close Higher As Nasdaq Reclaims The 8,000-mark After ..
DJ
04/16JOHNSON & JOHNSON : Pharmaceuticals drive J&J to better-than-expected quarterly ..
RE
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
04/19TEVA PHARMACEUTICAL INDUSTRIES : Pharma Gets FDA Approval to Market Generic Nasa..
DJ
04/18Pfizer, Lilly Release Top-Line Results From Phase 3 Study of Tanezumab for Os..
DJ
04/18Pfizer, Johnson & Johnson Weigh on Pharmaceutical ETFs
DJ
04/17ACREAGE : Canopy Growth nearing deal to buy U.S.-based pot company Acreage Holdi..
RE
04/17MERCK AND : on Pace for Largest Percent Decrease in Over a Year -- Data Talk
DJ
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 147 $
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 445
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055
ELI LILLY AND COMPANY-0.45%119 326